A Study of TJ003234 in Rheumatoid Arthritis Patients
A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single Ascending Dose and Multiple Ascending Doses of TJ003234 in Rheumatoid Arthritis Patients
Sponsor: I-Mab Biopharma US Limited
This PHASE1 trial investigates Rheumatoid Arthritis and is currently ongoing. I-Mab Biopharma US Limited leads this study, which shows 9 recorded versions since 2020 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Unknown PHASE1
Status: Recruiting → Unknown
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE1
-
Jun 2024 — Jul 2024 [monthly]
Recruiting PHASE1
-
Sep 2022 — Jun 2024 [monthly]
Recruiting PHASE1
-
Mar 2021 — Sep 2022 [monthly]
Recruiting PHASE1
▶ Show 4 earlier versions
-
Jan 2021 — Mar 2021 [monthly]
Recruiting PHASE1
-
Oct 2020 — Jan 2021 [monthly]
Recruiting PHASE1
-
Sep 2020 — Oct 2020 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Aug 2020 — Sep 2020 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- I-Mab Biopharma US Limited
For direct contact, visit the study record on ClinicalTrials.gov .